UK places order for 60m doses of Sanofi/GSK’s COVID-19 vaccineThe UK government has signed its fourth coronavirus vaccine deal, snapping up 60 million doses of an experimental Share XUK places order for 60m doses of Sanofi/GSK’s COVID-19 vaccinehttps://pharmaphorum.com/news/uk-places-order-for-60m-doses-of-sanofi-gsks-covid-19-vaccine/
Gilead’s Kite gains some height after second CAR-T approval in USGilead’s $11.9 billion purchase of Kite Pharma in 2017 didn’t follow the script, with two big write-downs in Share XGilead’s Kite gains some height after second CAR-T approval in UShttps://pharmaphorum.com/news/gileads-kite-gains-some-height-after-second-car-t-approval-in-us/
CHMP gives nod to GSK’s BCMA drug Blenrep for myelomaGlaxoSmithKline is closing in on EU approval for its first-in-class BCMA-targeting drug Blenrep, after getting a green light Share XCHMP gives nod to GSK’s BCMA drug Blenrep for myelomahttps://pharmaphorum.com/news/chmp-gives-nod-to-gsks-bcma-drug-blenrep-for-myeloma/
US places $1.95 billion order for Pfizer/BioNTech’s COVID-19 vaccineThe US government has agreed to pay Pfizer and BioNTech $1.95 billion to secure access to 100 million Share XUS places $1.95 billion order for Pfizer/BioNTech’s COVID-19 vaccinehttps://pharmaphorum.com/news/us-places-1-95-billion-order-for-pfizer-biontechs-covid-19-vaccine/
Controversy as pharma execs predict profits from COVID-19 vaccinesConcerns have emerged about access to some potential COVID-19 vaccines after pharma executives from three companies said they Share XControversy as pharma execs predict profits from COVID-19 vaccineshttps://pharmaphorum.com/news/controversy-as-pharma-execs-predict-profits-from-covid-19-vaccines/
Pandemic hits sales at Novartis after strong launch for SMA gene therapyThe COVID-19 pandemic has bit into sales at Novartis, the big Swiss pharma said in second quarter results, Share XPandemic hits sales at Novartis after strong launch for SMA gene therapyhttps://pharmaphorum.com/news/pandemic-hits-sales-at-novartis-after-strong-launch-for-gene-therapy/
NICE backs NHS use for Astellas’ Xospata after rethinkNICE has recommended regular NHS funding for Astellas’ Xospata (gilteritinib) monotherapy for certain adult patients with acute myeloid leukaemia. In final draft guidance Share XNICE backs NHS use for Astellas’ Xospata after rethinkhttps://pharmaphorum.com/news/nice-backs-nhs-use-for-astellas-xospata-after-rethink/
UK patients get early access to Alnylam’s ultra-rare disease drug lumasiranThe UK’s regulator has granted early access to Alnylam’s ultra-rare disease drug lumasiran, allowing patients with primary hyperoxaluria Share XUK patients get early access to Alnylam’s ultra-rare disease drug lumasiranhttps://pharmaphorum.com/news/uk-patients-get-early-access-to-alnylams-ultra-rare-disease-drug-lumasiran/
Mallinckrodt’s liver disease drug terlipressin edges FDA advisory panelAn FDA advisory committee has narrowly voted in favour of approval of Mallinckrodt’s terlipressin for hepatorenal syndrome type Share XMallinckrodt’s liver disease drug terlipressin edges FDA advisory panelhttps://pharmaphorum.com/news/mallinckrodts-liver-disease-drug-terlipressin-edges-fda-advisory-panel/
FDA reviewer warns of eye trouble with GSK’s myeloma ADCGlaxoSmithKline heads for an FDA advisory committee meeting this week for belantamab mafodotin – its much-touted treatment for Share XFDA reviewer warns of eye trouble with GSK’s myeloma ADChttps://pharmaphorum.com/news/fda-reviewer-warns-of-eye-trouble-with-gsks-myeloma-adc/
NICE backs NHS use of Takeda’s Adcetris for rare blood cancerTakeda’s antibody-drug conjugate Adcetris can now be routinely available on the NHS to patients with a rare form Share XNICE backs NHS use of Takeda’s Adcetris for rare blood cancerhttps://pharmaphorum.com/news/nice-backs-nhs-use-of-takedas-adcetris-for-rare-blood-cancer/
US snaps up first supplies of Regeneron’s COVID-19 antibodyHard on the heels of Regeneron moving its COVID-19 antibody cocktail into late-stage testing, the US government has Share XUS snaps up first supplies of Regeneron’s COVID-19 antibodyhttps://pharmaphorum.com/news/us-snaps-up-first-supplies-of-regenerons-covid-19-antibody/
Chasing Merck, Eisai launches insomnia drug Dayvigo in JapanEisai has launched its insomnia drug Dayvigo in Japan, the second in a new class of medicines after Share XChasing Merck, Eisai launches insomnia drug Dayvigo in Japanhttps://pharmaphorum.com/news/chasing-merck-eisai-launches-insomnia-drug-dayvigo-in-japan/
GSK and Sanofi close in on £500m COVID-19 vaccine deal with UK – reportGlaxoSmithKline and Sanofi are close to agreeing a £500m deal to supply the UK government with 60 million Share XGSK and Sanofi close in on £500m COVID-19 vaccine deal with UK – reporthttps://pharmaphorum.com/news/gsk-and-sanofi-close-in-on-500m-covid-19-vaccine-deal-with-uk-report/
ViiV gets FDA nod for Rukobia drug for older HIV patientsThe FDA has approved Rukobia, a first-in-class drug from ViiV Healthcare intended for older people with HIV, who Share XViiV gets FDA nod for Rukobia drug for older HIV patientshttps://pharmaphorum.com/news/viiv-gets-fda-nod-for-rukobia-drug-for-older-hiv-patients/
Survey shows patients wait six times longer than EU neighbours for new drugsPatients in some European countries are waiting up to six times longer for access to medicines than their neighbours, Share XSurvey shows patients wait six times longer than EU neighbours for new drugshttps://pharmaphorum.com/news/survey-shows-patients-wait-six-times-longer-than-eu-neighbours-for-new-drugs/
Novartis pays $678 million to settle US kickback allegationsAnother nail has been hammered into the coffin of the pharma model of providing lavish entertainment and other Share XNovartis pays $678 million to settle US kickback allegationshttps://pharmaphorum.com/news/novartis-pays-678-million-to-settle-us-kickback-allegations/
US government buys most of world’s supply of COVID-19 drug remdesivirThe US government has acquired most of the global supply of Gilead’s COVID-19 drug remdesivir until September as Share XUS government buys most of world’s supply of COVID-19 drug remdesivirhttps://pharmaphorum.com/news/us-government-buys-most-of-worlds-supply-of-covid-19-drug-remdesivir/
